Publication:
Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis.

cris.virtualsource.author-orcid101f1394-72d5-4dda-b28f-666a3dee6c70
cris.virtualsource.author-orcid149dd13d-6e82-4d6b-ab5b-24db3872c3d0
dc.contributor.authorWernly, Bernhard
dc.contributor.authorKarami, Mina
dc.contributor.authorEngström, Annemarie E
dc.contributor.authorWindecker, Stephan
dc.contributor.authorHunziker Munsch, Lukas Christoph
dc.contributor.authorLüscher, Thomas F
dc.contributor.authorHenriques, Jose P
dc.contributor.authorFerrari, Markus W
dc.contributor.authorBinnebößel, Stephan
dc.contributor.authorMasyuk, Maryna
dc.contributor.authorNiederseer, David
dc.contributor.authorAbel, Peter
dc.contributor.authorFuernau, Georg
dc.contributor.authorFranz, Marcus
dc.contributor.authorKelm, Malte
dc.contributor.authorBusch, Mathias C
dc.contributor.authorFelix, Stephan B
dc.contributor.authorThiele, Holger
dc.contributor.authorLauten, Alexander
dc.contributor.authorJung, Christian
dc.date.accessioned2024-10-07T05:36:11Z
dc.date.available2024-10-07T05:36:11Z
dc.date.issued2021-04
dc.description.abstractAIMS The mortality in cardiogenic shock (CS) is high. The role of specific mechanical circulatory support (MCS) systems is unclear. We aimed to compare patients receiving Impella versus ECLS (extracorporal life support) with regard to baseline characteristics, feasibility, and outcomes in CS. METHODS AND RESULTS This is a retrospective cohort study including CS patients over 18 years with a complete follow-up of the primary endpoint and available baseline lactate level, receiving haemodynamic support either by Impella 2.5 or ECLS from two European registries. The decision for device implementation was made at the discretion of the treating physician. The primary endpoint of this study was all-cause mortality at 30 days. A propensity score for the use of Impella was calculated, and multivariable logistic regression was used to obtain adjusted odds ratios (aOR). In total, 149 patients were included, receiving either Impella (n = 73) or ECLS (n = 76) for CS. The feasibility of device implantation was high (87%) and similar (aOR: 3.14; 95% CI: 0.18-56.50; P = 0.41) with both systems. The rates of vascular injuries (aOR: 0.95; 95% CI: 0.10-3.50; P = 0.56) and bleedings requiring transfusions (aOR: 0.44; 95% CI: 0.09-2.10; P = 0.29) were similar in ECLS patients and Impella patients. The use of Impella or ECLS was not associated with increased odds of mortality (aOR: 4.19; 95% CI: 0.53-33.25; P = 0.17), after correction for propensity score and baseline lactate level. Baseline lactate level was independently associated with increased odds of 30 day mortality (per mmol/L increase; OR: 1.29; 95% CI: 1.14-1.45; P < 0.001). CONCLUSIONS In CS patients, the adjusted mortality rates of both ECLS and Impella were high and similar. The baseline lactate level was a potent predictor of mortality and could play a role in patient selection for therapy in future studies. In patients with profound CS, the type of device is likely to be less important compared with other parameters including non-cardiac and neurological factors.
dc.description.numberOfPages9
dc.description.sponsorshipUniversitätsklinik für Kardiologie
dc.identifier.doi10.48350/163223
dc.identifier.pmid33560591
dc.identifier.publisherDOI10.1002/ehf2.13200
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/59045
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofESC Heart Failure
dc.relation.issn2055-5822
dc.relation.organizationDCD5A442BB15E17DE0405C82790C4DE2
dc.subjectCardiogenic shock ECMO Extracorporeal life support Impella Mechanical circulatory support
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleImpella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage961
oaire.citation.issue2
oaire.citation.startPage953
oaire.citation.volume8
oairecerif.author.affiliationUniversitätsklinik für Kardiologie
oairecerif.author.affiliationUniversitätsklinik für Kardiologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-01-20 14:23:48
unibe.description.ispublishedpub
unibe.eprints.legacyId163223
unibe.journal.abbrevTitleESC Heart Failure
unibe.refereedTRUE
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Impella_versus_extracorporal.pdf
Size:
230.55 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc/4.0
Content:
published

Collections